FCGR2A and infection: These include – a) infection enhancement-based ADE assay in FcγRIIa expressing K562, U937 and Vero-CD32a cells, b) ADE by foci-reduction neutralization test in non-FcγR expressing Vero and FcγRIIa expressing Vero-CD32a cells.